Tirzepatide vs Liraglutide
Which Is Right for You? Complete Comparison (2026)
Tirzepatide vs liraglutide comparison — dual GLP-1/GIP weekly injection vs daily GLP-1 alone, 22% vs 8% weight loss, metabolic benefits, side effects.
Tirzepatide vs Liraglutide: At a Glance
- ✓Dual GIP + GLP-1 receptor agonist — first in class
- ✓GIP agonism enhances insulin sensitivity in adipose tissue
- ✓~21% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg)
- ✓GIP may moderate GI side effects vs GLP-1-only drugs
- ✓Half-life ~5 days — once-weekly injection
- ✓First-generation daily GLP-1 receptor agonist
- ✓FDA-approved for T2D (Victoza 1.8 mg) and obesity (Saxenda 3.0 mg)
- ✓~8% mean weight loss at 56 weeks (SCALE, 3.0 mg)
- ✓Positive cardiovascular outcome data (LEADER trial)
- ✓Requires daily injection (vs weekly for semaglutide)
Detailed Comparison
| Feature | Tirzepatide | Liraglutide |
|---|---|---|
| Mechanism | Dual GIP/GLP-1 receptor agonist | GLP-1 receptor agonistBest |
| Dosing | 2.5-15 mg SC weekly | 0.6-3.0 mg SC daily |
| Administration | Subcutaneous injection weekly | Subcutaneous injection daily |
| Half-life | ~5 days | ~13 hours — requires daily dosing |
| FDA Status | FDA-approved: Mounjaro (T2D), Zepbound (obesity) | FDA-approved: Victoza (T2D), Saxenda (obesity) |
| Key Trial | Jastreboff AM et al. NEJM 2022 (SURMOUNT-1) — 20.9% weight loss | Pi-Sunyer X et al. NEJM 2015 (SCALE) — 8% weight loss |
| Side Effects | Nausea (31%), vomiting, diarrhea, constipation | Nausea, vomiting, diarrhea — similar to semaglutide |
Which Should You Choose?
Tirzepatide (dual gip/glp-1 receptor agonist) and Liraglutide (glp-1 receptor agonist) serve different clinical roles despite both being in the Dual GIP/GLP-1 agonist space. Tirzepatide first-in-class dual gip and glp-1 receptor agonist that activates two incretin pathways for enhanced weight loss and glycemic control vs single agonists. Liraglutide first-generation long-acting glp-1 receptor agonist with daily dosing.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Tirzepatide and Liraglutide
Choosing between Tirzepatide and Liraglutide depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Tirzepatide and Liraglutide is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Tirzepatide vs Liraglutide: Frequently Asked Questions
Tirzepatide is a dual gip/glp-1 receptor agonist while Liraglutide is a glp-1 receptor agonist. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Tirzepatide works as a dual gip/glp-1 receptor agonist (2.5-15 mg SC weekly), while Liraglutide is a glp-1 receptor agonist (0.6-3.0 mg SC daily). They have different half-lives (~5 days vs ~13 hours — requires daily dosing), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Tirzepatide or Liraglutide in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.
📚References & sources
Latest on Tirzepatide
Ozempic, Wegovy & Beyond: How GLP-1 Drugs Are Changing What We Eat
The rise of GLP-1 medications is profoundly altering consumer spending habits and food preferences, forcing the grocery industry to adapt. Discover the science behind these changes and how businesses are responding.
7 min read
Wegovy, Mounjaro & Your Libido: How GLP-1s Reshape Desire
GLP-1 medications have transformed weight management and diabetes care, but their effects extend beyond the scale. Many users report surprising changes to their libido and sexual function. This article delves into why these powerful drugs can either boost or dampen your sex drive, offering insights from leading medical experts.
9 min read
Ozempic & Wegovy's Shadow: The Rise of Gray Market Peptides
The surge in popularity of GLP-1 medications like Ozempic and Wegovy has inadvertently fueled a growing 'gray market' for peptides. This unregulated trade, often facilitated by cryptocurrency, presents significant risks to consumers seeking cheaper alternatives or unapproved compounds.
6 min read